We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Collaboration on Motion Management Tool for Intensity-Modulated Proton Therapy

By MedImaging International staff writers
Posted on 08 May 2013
Print article
Varian Medical Systems (Palo Alto, CA, USA) and Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are collaborating on to further develop motion management techniques for proton therapy.

The multiyear agreement, geared at enhancing treatment approaches for tumors in the pancreas, liver, lung, and breast, will evaluate approaches using a four-dimensional (4D) treatment-planning simulator developed by PSI.

Proton therapy involves the use of a controlled beam of protons to target tumors with higher levels of precision than is possible with other forms of radiation therapy, potentially limiting damage to healthy surrounding tissue. The Paul Scherrer Institute is an innovator in the development of intensity- modulated proton therapy (IMPT) techniques, and specializes in the treatment of pediatric patients. “We hope to exploit our unique methods for simulating clinically realistic organ motions for the study of motion mitigation techniques for spot scanned proton therapy,” stated Prof. Tony Lomax from PSI. “This project will utilize 4D motion data sets and dose calculations that can uniquely model patient motion variations that are difficult to capture with conventional data sets.”

“Varian’s ProBeam proton system was developed in collaboration with the PSI,” stated Moataz Karmalawy, general manager of Varian’s particle therapy division. “We are delighted to expand our partnership with this internationally respected institute to include the development of indications-specific solutions. This collaboration will support our customers in the fight against cancers that have not typically been treated with proton therapy in the past.”

The capability to treat moving tumors is increasingly important for proton therapy facilities worldwide. “When testing motion mitigation techniques, it’s important to have a tool that can simulate the timed dose delivery for realistic tumor cases to determine the relative merit of the different techniques,” said Jan Timmer, marketing director for Varian particle therapy. “PSI has developed excellent software for 4D treatment planning and we want to support its further development and the ongoing evaluation of motion management techniques.”

CE marking and international registrations are still pending for ProBeam. The system is not yet available for sale in all markets.

Varian Medical Systems, Inc. is a world-leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers, and medical oncology practices.

PSI operates the first compact scanning gantry worldwide for proton radiation therapy of deep-seated tumors. The spot-scanning technique developed at PSI enables malignant tumors to be targeted with high precision deep inside in the body without damaging healthy tissue around the target area. By end of 2011, the PSI compact Gantry 1 had been used to treat more than 800 patients suffering from brain, skull-base or spinal cord tumors as well as abdominal sarcomas. Among the patients were more than 200 children and young people under the age of 20. PSI has treated children since 2004.

Related Links:
Varian Medical Systems
Paul Scherrer Institute

New
Mobile X-Ray Machine
MARS 15 / 30
New
MRI Infusion Workstation
BeneFusion MRI Station
New
Leg Wraps
Leg Wraps
New
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector

Print article

Channels

Radiography

view channel
Image: AI can identify “mammographically-visible” types of interval cancers earlier by flagging them at the time of screening (Photo courtesy of ScreenPoint Medical)

AI Improves Early Detection of Interval Breast Cancers

Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more

MRI

view channel
Image: An MRI scan can reveal a heart’s functional age (Photo courtesy of 123RF)

New MRI Technique Reveals True Heart Age to Prevent Attacks and Strokes

Heart disease remains one of the leading causes of death worldwide. Individuals with conditions such as diabetes or obesity often experience accelerated aging of their hearts, sometimes by decades.... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.